PET imaging study for people getting CAR-T therapy for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a special PET imaging agent (64Cu-GRIP B) to see if it can help track how well CAR-T therapy is working in people with non-Hodgkin lymphoma. It is for patients who have had at least one prior treatment and are scheduled to receive a standard CD19-targeting CAR-T product.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma (non-Hodgkin lymphoma) that has come back or not responded to at least one prior treatment.
- You are planning to get a standard CAR-T cell therapy that targets a protein called CD19.
- You are willing to have a biopsy (tissue sample) from a tumor after treatment, and you have a soft-tissue tumor that can be safely biopsied.
- You are 18 years old or older.
- You are able to understand and agree to the study procedures (sign a consent form).
- You have a good activity level (ECOG score less than 2, meaning you can do most daily activities yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.